About Immunocore
Immunocore is a company based in Abingdon (United Kingdom) founded in 2008 by Nicholas John Cross and George Kelly Martin.. Immunocore has raised $601.28 million across 9 funding rounds from investors including Lilly, WuXi AppTec and BlackRock. The company has 493 employees as of December 31, 2024. Immunocore operates in a competitive market with competitors including Senti Biosciences, Caribou Biosciences, Autolus, Cargo Therapeutics and Achilles Therapeutics, among others.
- Headquarter Abingdon, United Kingdom
- Employees 493 as on 31 Dec, 2024
- Founders Nicholas John Cross, George Kelly Martin
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
-
Annual Revenue
$310.33 M23.94as on Dec 31, 2024
-
Net Profit
$-51.11 M7.91as on Dec 31, 2024
-
EBITDA
$-66.28 M-18.87as on Dec 31, 2024
-
Total Equity Funding
$601.28 M (USD)
in 9 rounds
-
Latest Funding Round
$140 M (USD), Post-IPO
Jul 18, 2022
-
Investors
Lilly
& 12 more
-
Employee Count
493
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Immunocore
Immunocore is a publicly listed company on the NASDAQ with ticker symbol IMCR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Immunocore
Immunocore has successfully raised a total of $601.28M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $140 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $140.0M
-
First Round
First Round
(30 Sep 2008)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2022 | Amount | Post-IPO - Immunocore | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Immunocore | Valuation |
investors |
|
| Jan, 2021 | Amount | Debt – Conventional - Immunocore | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Immunocore
Immunocore has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, WuXi AppTec and BlackRock. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Founded Year | Domain | Location | |
|
Private equity fund focused on global markets
|
Founded Year | Domain | Location | |
|
Companies developing T1D products are funded through venture philanthropy.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Immunocore
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Immunocore
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immunocore Comparisons
Competitors of Immunocore
Immunocore operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Caribou Biosciences, Autolus, Cargo Therapeutics and Achilles Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| domain | founded_year | HQ Location |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| domain | founded_year | HQ Location |
Cell-based therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T-cell therapies targeting tumor neo-antigens for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immunocore
Frequently Asked Questions about Immunocore
When was Immunocore founded?
Immunocore was founded in 2008.
Where is Immunocore located?
Immunocore is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
Is Immunocore a funded company?
Immunocore is a funded company, having raised a total of $601.28M across 9 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $100M, raised on Sep 30, 2008.
How many employees does Immunocore have?
As of Dec 31, 2024, the latest employee count at Immunocore is 493.
What is the annual revenue of Immunocore?
Annual revenue of Immunocore is $310.33M as on Dec 31, 2024.
What does Immunocore do?
Immunocore was founded in 2008 in Abingdon, United Kingdom, within the biotechnology sector focused on oncology. Proprietary ImmTAC molecules are developed to mobilize the immune system against cancer cells by targeting peptide-HLA complexes and triggering T-cell responses via anti-CD3 fragments. Operations center on advancing bi-specific immunotherapeutics, with the lead candidate IMCgp100 directed toward uveal melanoma treatment.
Who are the top competitors of Immunocore?
Immunocore's top competitors include Achilles Therapeutics, Autolus and Senti Biosciences.
Is Immunocore publicly traded?
Yes, Immunocore is publicly traded on NASDAQ under the ticker symbol IMCR.
Who are Immunocore's investors?
Immunocore has 13 investors. Key investors include Lilly, WuXi AppTec, BlackRock, General Atlantic, and Gates Foundation.
What is Immunocore's ticker symbol?
The ticker symbol of Immunocore is IMCR on NASDAQ.
What is Immunocore's valuation?
The valuation of Immunocore is $777.28M as of Jul 2015.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.